SBP-1750

• Description :

  SBP-1750 is an orally active ULK inhibitor and an ATG13 degrader. SBP-1750 strongly inhibits ULK1/2 activity, with IC50 values of 8 and 50 nM, respectively. SBP-1750 induces ATG13 degradation, with an EC50 value of 114 nM. SBP-1750 can inhibit autophagy in cancer cells and induce cell death. SBP-1750 can be used in cancer research, such as for pancreatic cancer[1].

• UNSPSC :

  12352005

• Target :

  ULK

• Related Pathways :

  Autophagy

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Purity :

  98.05

• Smiles :

  O=C(NC)C1=CC=CC=C1NC2=NC(NC3=CC(OC)=C(OC)C(OC)=C3)=NC=C2Cl

• Molecular Formula :

  C21H22ClN5O4

• Molecular Weight :

  443.88

• References & Citations :

  [1]Hagan PM, et al. ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers. bioRxiv [Preprint]. 2025 Oct 15:2025.10.14.682402.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  ULK1; ULK2

• CAS Number :

  [1884219-70-8]